{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:00:29Z","timestamp":1791122429738,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Allogeneic stem cell transplantation (allo HCT) is a curative treatment for follicular lymphoma, but is hampered by a relatively high treatment-related mortality and by difficulties in identifying high-risk groups for whom transplant is warranted. Results with myeloablative conditioning have improved, but the field has shifted largely to reduced-intensity conditioning and non-myeloablative transplantation, though morbidity and mortality are also substantial. Some groups have investigated T cell\u2013depleted transplantation, which results in a low rate of chronic graft-versus-host disease (GVHD) and, in most studies, excellent rates of disease control. Overall, outcome after alloHCT for follicular lymphoma correlates more with disease status, with performance status and with comorbidities than with any particular conditioning regimen used. For patients with chemotherapy-sensitive disease, the treatment-related mortality has stabilized in the 15% to 20% range and, depending on the method of GVHD prophylaxis and the donor type, there is an additional 20% to 60% incidence of chronic GVHD. For patients with chemotherapy-refractory disease, both treatment-related mortality and recurrence rates are much higher, but their prognosis is dismal with other treatments and some may be cured, particularly with myeloablative transplants. Ongoing studies focus on improving conditioning regimens, on prevention of disease recurrence and on decreasing chronic GVHD.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.610","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"610-618","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy"],"prefix":"10.1182","volume":"2009","author":[{"given":"Koen","family":"van Besien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111705085398000_R1","doi-asserted-by":"crossref","unstructured":"Van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low grade lymphoma - the case for aggressive management. J Clin Oncol. 1995;13:1096\u20131102.","DOI":"10.1200\/JCO.1995.13.5.1096"},{"key":"2019111705085398000_R2","doi-asserted-by":"crossref","unstructured":"van Besien K, Champlin IK, McCarthy P. Allogeneic transplantation for low-grade lymphoma: long-term follow-up [letter]. J Clin Oncol. 2000;18:702\u2013703.","DOI":"10.1200\/JCO.2000.18.3.702"},{"key":"2019111705085398000_R3","doi-asserted-by":"crossref","unstructured":"Toze Cl, Shepherd JD, Connors JM, et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant. 2000;25:605\u2013612.","DOI":"10.1038\/sj.bmt.1702191"},{"key":"2019111705085398000_R4","unstructured":"Forrest D, Matheson K, Couban S, Nevill T, Fernandez L. High dose therapy and allogeneic hematopietic stem cell transplantation for progressive follicular lymphoma [abstract]. Blood. 2001;98:408."},{"key":"2019111705085398000_R5","doi-asserted-by":"crossref","unstructured":"Stein RS, Greer JP, Goodman S, et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant. 1999;23:227\u2013233.","DOI":"10.1038\/sj.bmt.1701556"},{"key":"2019111705085398000_R6","unstructured":"van Besien K, Sobocinski K, Rowlings P, et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood. 1998;92:1832\u20131836."},{"key":"2019111705085398000_R7","doi-asserted-by":"crossref","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667\u2013678.","DOI":"10.1038\/sj.bmt.1703891"},{"key":"2019111705085398000_R8","doi-asserted-by":"crossref","unstructured":"van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521\u20133529.","DOI":"10.1182\/blood-2003-04-1205"},{"key":"2019111705085398000_R9","doi-asserted-by":"crossref","unstructured":"Kuruvilla J, Pond G, Tsang R, et al. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant. 2008;14:775\u2013782.","DOI":"10.1016\/j.bbmt.2008.04.007"},{"key":"2019111705085398000_R10","doi-asserted-by":"crossref","unstructured":"van Besien K, Carreras J, Bierman PJ, et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009;15:554\u2013563.","DOI":"10.1016\/j.bbmt.2009.01.012"},{"key":"2019111705085398000_R11","doi-asserted-by":"crossref","unstructured":"Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550\u20131558.","DOI":"10.1182\/blood-2004-03-0804"},{"key":"2019111705085398000_R12","doi-asserted-by":"crossref","unstructured":"Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810\u20131814.","DOI":"10.1182\/blood-2004-05-1947"},{"key":"2019111705085398000_R13","doi-asserted-by":"crossref","unstructured":"Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304\u20132312.","DOI":"10.1038\/sj.leu.2403967"},{"key":"2019111705085398000_R14","doi-asserted-by":"crossref","unstructured":"Baron F, Storb R. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Best Pract Res Clin Haematol. 2006;19:637\u2013653.","DOI":"10.1016\/j.beha.2006.06.002"},{"key":"2019111705085398000_R15","doi-asserted-by":"crossref","unstructured":"Mandigers CM, Verdonck LF, Meijerink JP, et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159\u20131163.","DOI":"10.1038\/sj.bmt.1704290"},{"key":"2019111705085398000_R16","doi-asserted-by":"crossref","unstructured":"Russell NH, Byrne JL, Faulkner RD, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36:437\u2013441.","DOI":"10.1038\/sj.bmt.1705074"},{"key":"2019111705085398000_R17","doi-asserted-by":"crossref","unstructured":"Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:50\u201358.","DOI":"10.1016\/j.bbmt.2007.04.013"},{"key":"2019111705085398000_R18","doi-asserted-by":"crossref","unstructured":"Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:211\u2013217.","DOI":"10.1200\/JCO.2007.11.5477"},{"key":"2019111705085398000_R19","doi-asserted-by":"crossref","unstructured":"Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111:446\u2013452.","DOI":"10.1182\/blood-2007-07-098483"},{"key":"2019111705085398000_R20","doi-asserted-by":"crossref","unstructured":"Artz A, Pollyea D, Kocherginsky M, et al. Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant2006;12:954\u2013964.","DOI":"10.1016\/j.bbmt.2006.05.015"},{"key":"2019111705085398000_R21","doi-asserted-by":"crossref","unstructured":"Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992\u20132001.","DOI":"10.1002\/cncr.23375"},{"key":"2019111705085398000_R22","doi-asserted-by":"crossref","unstructured":"Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530\u20135536.","DOI":"10.1182\/blood-2008-01-136242"},{"key":"2019111705085398000_R23","doi-asserted-by":"crossref","unstructured":"Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14:418\u2013425.","DOI":"10.1016\/j.bbmt.2008.01.008"},{"key":"2019111705085398000_R24","doi-asserted-by":"crossref","unstructured":"Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant. 2006;12:1326\u20131334.","DOI":"10.1016\/j.bbmt.2006.08.035"},{"key":"2019111705085398000_R25","doi-asserted-by":"crossref","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310\u20134316.","DOI":"10.1182\/blood-2001-11-0107"},{"key":"2019111705085398000_R26","doi-asserted-by":"crossref","unstructured":"Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant. 2005;36:205\u2013213.","DOI":"10.1038\/sj.bmt.1705027"},{"key":"2019111705085398000_R27","doi-asserted-by":"crossref","unstructured":"Vigouroux S, Michallet M, Porcher R et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007;92:627\u2013634.","DOI":"10.3324\/haematol.10924"},{"key":"2019111705085398000_R28","doi-asserted-by":"crossref","unstructured":"Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14:236\u2013245.","DOI":"10.1016\/j.bbmt.2007.11.004"},{"key":"2019111705085398000_R29","doi-asserted-by":"crossref","unstructured":"Bierman PJ, Sweetenham JW, Loberiza FM, et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin\u2019s lymphoma: a comparison with allogeneic and autologous transplantation. J Clin Oncol. 2003;21:3744\u20133753.","DOI":"10.1200\/JCO.2003.08.054"},{"key":"2019111705085398000_R30","doi-asserted-by":"crossref","unstructured":"Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784\u20133792.","DOI":"10.1182\/blood-2007-03-082933"},{"key":"2019111705085398000_R31","doi-asserted-by":"crossref","unstructured":"Juckett M, Rowlings P, Hessner M, et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin\u2019s lymphoma: clinical and molecular follow-up. Bone Marrow Transplant. 1998;21:893\u2013899.","DOI":"10.1038\/sj.bmt.1701209"},{"key":"2019111705085398000_R32","doi-asserted-by":"crossref","unstructured":"Mandigers CM, Raemaekers JM, Schattenberg AV, et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin\u2019s lymphoma. Br J Haematol. 1998;100:198\u2013206.","DOI":"10.1046\/j.1365-2141.1998.00539.x"},{"key":"2019111705085398000_R33","doi-asserted-by":"crossref","unstructured":"Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin\u2019s lymphoma: updated results of the Utrecht experience. Leuk Lymphoma. 1999;34:129\u2013136.","DOI":"10.3109\/10428199909083388"},{"key":"2019111705085398000_R34","doi-asserted-by":"crossref","unstructured":"Novitzky N, Thomas V. Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies. Biol Blood Marrow Transplant. 2007;13:107\u2013115.","DOI":"10.1016\/j.bbmt.2006.09.004"},{"key":"2019111705085398000_R35","doi-asserted-by":"crossref","unstructured":"Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol. 2008;141:235\u2013243.","DOI":"10.1111\/j.1365-2141.2008.07067.x"},{"key":"2019111705085398000_R36","doi-asserted-by":"crossref","unstructured":"Morris E, Thomson K, Craddock C, et al. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin\u2019s lymphoma (NHL). Blood. 2004;104:3865\u20133871.","DOI":"10.1182\/blood-2004-03-1105"},{"key":"2019111705085398000_R37","doi-asserted-by":"crossref","unstructured":"Gopal AK, Pagel JM, Rajendran JG, et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant. 2006;12:697\u2013702.","DOI":"10.1016\/j.bbmt.2006.03.014"},{"key":"2019111705085398000_R38","doi-asserted-by":"crossref","unstructured":"Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains anti-tumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114:1099\u20131109.","DOI":"10.1182\/blood-2009-03-211441"},{"key":"2019111705085398000_R39","doi-asserted-by":"crossref","unstructured":"Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008;26:5767\u20135774.","DOI":"10.1200\/JCO.2008.17.7279"},{"key":"2019111705085398000_R40","doi-asserted-by":"crossref","unstructured":"Kornacker M, Stumm J, Pott C, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20:722\u2013728.","DOI":"10.1093\/annonc\/mdn691"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/610\/645608\/610_618ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/610\/645608\/610_618ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T10:09:12Z","timestamp":1573985352000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/610\/19871\/Allogeneic-stem-cell-transplantation-in-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.610","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}